DK2585833T3 - Fremgangsmåder til detektering af cancer - Google Patents
Fremgangsmåder til detektering af cancer Download PDFInfo
- Publication number
- DK2585833T3 DK2585833T3 DK11798823.8T DK11798823T DK2585833T3 DK 2585833 T3 DK2585833 T3 DK 2585833T3 DK 11798823 T DK11798823 T DK 11798823T DK 2585833 T3 DK2585833 T3 DK 2585833T3
- Authority
- DK
- Denmark
- Prior art keywords
- tag
- pmg
- cancer
- cer
- bmp
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 84
- 201000011510 cancer Diseases 0.000 title claims description 67
- 238000000034 method Methods 0.000 title claims description 63
- 238000001514 detection method Methods 0.000 title description 3
- 150000002632 lipids Chemical class 0.000 claims description 190
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 54
- 201000005202 lung cancer Diseases 0.000 claims description 54
- 208000020816 lung neoplasm Diseases 0.000 claims description 54
- 206010006187 Breast cancer Diseases 0.000 claims description 53
- 208000026310 Breast neoplasm Diseases 0.000 claims description 53
- 210000001124 body fluid Anatomy 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 18
- 210000002381 plasma Anatomy 0.000 claims description 13
- 238000000513 principal component analysis Methods 0.000 claims description 12
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 10
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 238000004252 FT/ICR mass spectrometry Methods 0.000 claims description 9
- 238000010239 partial least squares discriminant analysis Methods 0.000 claims description 9
- YBHMPNRDOVPQIN-UHFFFAOYSA-N (13E,15S)-15-Hydroxy-9-oxo-8(12),13-prostadienoic acid Natural products CCCCCC(O)C=CC1=C(CCCCCCC(O)=O)C(=O)CC1 YBHMPNRDOVPQIN-UHFFFAOYSA-N 0.000 claims description 7
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 claims description 7
- 102100036465 Autoimmune regulator Human genes 0.000 claims description 7
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 238000004949 mass spectrometry Methods 0.000 claims description 7
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 claims description 7
- YBHMPNRDOVPQIN-VSOYFRJCSA-N prostaglandin B1 Chemical compound CCCCC[C@H](O)\C=C\C1=C(CCCCCCC(O)=O)C(=O)CC1 YBHMPNRDOVPQIN-VSOYFRJCSA-N 0.000 claims description 7
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 108010053763 Pyruvate Carboxylase Proteins 0.000 claims description 4
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 claims description 4
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 210000003567 ascitic fluid Anatomy 0.000 claims description 4
- 210000002939 cerumen Anatomy 0.000 claims description 4
- 210000003756 cervix mucus Anatomy 0.000 claims description 4
- 238000012937 correction Methods 0.000 claims description 4
- 210000003097 mucus Anatomy 0.000 claims description 4
- 238000010238 partial least squares regression Methods 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000009328 Perro Species 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 238000002790 cross-validation Methods 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 210000003060 endolymph Anatomy 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 210000004051 gastric juice Anatomy 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 210000004251 human milk Anatomy 0.000 claims description 3
- 235000020256 human milk Nutrition 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 201000010453 lymph node cancer Diseases 0.000 claims description 3
- 238000010801 machine learning Methods 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 210000000019 nipple aspirate fluid Anatomy 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 210000004049 perilymph Anatomy 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002374 sebum Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims 4
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 description 338
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 294
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 77
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 77
- 150000002759 monoacylglycerols Chemical class 0.000 description 34
- 241000282412 Homo Species 0.000 description 16
- 125000002252 acyl group Chemical group 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 150000008105 phosphatidylcholines Chemical class 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 150000003905 phosphatidylinositols Chemical class 0.000 description 5
- 229940067626 phosphatidylinositols Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- -1 PC-pmg Chemical class 0.000 description 4
- 238000004896 high resolution mass spectrometry Methods 0.000 description 4
- 150000008106 phosphatidylserines Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000004910 pleural fluid Anatomy 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 125000003473 lipid group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000004909 pre-ejaculatory fluid Anatomy 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010036781 Fumarate Hydratase Proteins 0.000 description 1
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 101000840556 Oryza sativa subsp. japonica Hexokinase-4, chloroplastic Proteins 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 102000012435 Phosphofructokinase-1 Human genes 0.000 description 1
- 108010022684 Phosphofructokinase-1 Proteins 0.000 description 1
- 102000012434 Phosphofructokinase-2 Human genes 0.000 description 1
- 108010022678 Phosphofructokinase-2 Proteins 0.000 description 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102000011929 Succinate-CoA Ligases Human genes 0.000 description 1
- 108010075728 Succinate-CoA Ligases Proteins 0.000 description 1
- 102100028601 Transaldolase Human genes 0.000 description 1
- 108020004530 Transaldolase Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 150000003313 saccharo lipids Chemical class 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (22)
1. Fremgangsmåde til at bestemme tilstedeværelse eller fravær af mindst en cancertype i et dyr, hvilken fremgangsmåde omfatter: - at bestemme lipidmængder af lipider i et sæt af lipider i en prøve fra dyret, og - at bestemme tilstedeværelse eller fravær af mindst en cancertype i dyret med en prædiktiv model; hvor - lipidmængderne af lipider i lipidsættet omfatter et input af den prædiktive model, - prøven omfatter en kropsvæske eller behandling deraf, - den mindst ene cancertype er valgt fra gruppen, der består af carcinomer, sarcomer, hæmatologiske cancerformer, neurologiske maligniteter, skjoldbruskcancer, neuroblastom, melanom, nyrecellecarcinom, hepatocellulært carcinom, brystcancer, tyktarmscancer, lungecancer, cancer i bugspytkirtlen, hjernecancer, prostatacancer, kronisk lymfocytisk leukæmi, akut lymfoblastisk leukæmi, rhabdomyosarcoma, glioblastom multiforme, meningiom, blærecancer, gastrisk cancer, gliom, oral cancer, nasopharyngeal carcinoma, nyrecancer, rektal cancer, lymfeknudecancer, knoglemarvscancer, mavecancer, livmodercancer, leukæmi, basalcellecarcinom, cancer relateret til epithelceller, cancer, som kan ændre reguleringen eller aktiviteten af pyruvatcarboxylase og tumorer associeret med en hvilken som helst af de førnævnte cancertyper; - lipidsættet omfatter et lipid fra klassen BMP, fortrinsvis BMP (30: 1), BMP (32:
1), BMP (34: 1), BMP (35: 4), BMP (36: 3), BMP (37: 1), BMP (37: 7), BMP (38:
1) , BMP (38: 2), BMP (38: 4), BMP (39: 1), BMP (39: 4), BMP 40: 1), BMP (40:
2) , BMP (40: 3), BMP (40: 4), BMP (40: 7), BMP (42:10), BMP (42: 2), BMP: 5) eller BMP (44: 8) og den prædiktive model omfatter en eller flere af følgende: dimensionsreducerende fremgangsmåder, klyngefremgangsmåder, maskinindlæringsfremgangsmåder, principal komponentanalyse, blød uafhængig modellering af klasseanalogi, partielle mindste kvadraters regression, ortogonale mindste kvadraters regression, partielle mindste kvadraters diskriminantanalyse, ortogonale partielle mindste kvadraters diskriminantanalyse, gennemsnitlig centrering, mediancentrering, Pareto-skalering, enhedsvarianskalering, ortogonal signalkorrektion, integration, differentiering, krydsvalidering eller modtageroperationskarakteristiske kurver.
2. Fremgangsmåden ifølge krav 1, hvor kropsvæsken er valgt fra gruppen, der består plasmaopkastning, cerumen, mavesaft, modermælk, slim, spyt, talg, sæd, sved, tårer, vaginal sekretion, blodserum, vandig legemsvæske, glaslegemevæske, endolymfe, perilymfe, peritonealvæske, lungehindevæske, cerebrospinalvæske, blod, plasma, brystvorte-aspiratvæske, urin, afføring og bronchoalveolær skyllevæske.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor prøven omfatter en lipidmikrovesikelfraktion.
4. Fremgangsmåde ifølge krav 1,2 eller 3, hvor lipidsættet omfatter mindst 10, mindst 50, mindst 100, mindst 200 eller ikke mere end 100.000 lipider.
5. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor lipidsættet yderligere omfatter et eller flere lipider, der er udvalgt fra den ene eller de nævnte flere klasser af lipider, som er valgt fra gruppen, der består af CE, Cer, DAG, DH-LTB4, FA, GA2, GM3, HexCer, HexDHCer, LacCer, LysoPA, LysoPC, LysoPC-pmg, LysoPE, LysoPE-pmg, LysoPS, MAG, PC, PC-pmg, PE, PE-pmg, PGA1, PGB1, SM, Sphingosin, TAG og TH-12-keto -LTB4.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor lipidsættet yderligere omfatter et eller flere lipider, der er udvalgt fra den ene eller de nævnte flere klasser af lipider, som er valgt fra gruppen, der består af FA, MAG, DAG, TAG, PI, PE, PS, PI LysoPC, LysoPI, LysoPD, LysoPi, LysoPP, LysoPa, LysoPC, LysoPE, SM, Cer, Cer-P, HexCer, GA1, GA2, GD1, GD2, GM1, GM2, GM3, GT1 og CE.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor et eller flere lipider i lipidsættet er yderligere valgt fra gruppen bestående af CE (16: 2), CE (18: 2), CE (18: 3), CE 18: 4), CE (20: 2), CE (20: 4), CE (20: 5), Cer (32: 1), Cer (34: 1), Cer (36: 1), Cer (38: 1), Cer (38: 4), Cer (40; 2), Cer (40: 4), DAG (28: 0), DAG (32: 0), DAG (32: 2), DAG (34: 0), DAG (34: 3), DAG (34: 5), DAG (36: 0), DAG (36: 1), DAG (36: 2), DAG (36: 3), DAG (36: 8), DAG (38: 1), DAG (38: 10), DAG (38: 2), DAG (38: 3), DAG (38: 5), DAG (40: 1), DAG (40: 2) , DAG (40: 5), DH-LTB4 (20: 3), FA (16: 3), FA (19: 1), GA2 (30: 0), GA2 (33: 2), GA2 (35: 2), GA2 (37: 2), GM3 (41: 1), HexCer (32: 1), HexDHCer (34: 0), LacCer (30: 0), LacCer (30: 1), LacCer (32: 2) LysoPA (16: 2), LysoPA (16: 3), LysoPA (18: 1), LysoPA (22: 0), LysoPA (22: 1), LysoPC (16: 0), LysoPC (18: 0) LysoPC (18: 1), LysoPC (18: 4), LysoPC (20: 4), LysoPC (20: 5), LysoPC (26: 6), LysoPC-pmg (12: 0), LysoPC-pmg (18:3), LysoPC-pmg (24: 4), LysoPC-pmg (26: 0), LysoPE (10: 1), LysoPE (16: 2), LysoPE (18: 2), Lyso PE-pmg (18:
4), LysoPS (24: 1), MAG (18: 0), MAG (20: 3), MAG (24: 2), PC (32: 0), PC (32: 1) , PC (34: 1), PC (34: 2), PC (34: 3), PC (34: 4), PC (34: 6), PC (36: 1), PC (36: 2) PC (36: 3), PC (36: 4), PC (36: 5), PC (36: 6), PC (36: 9), PC(38:2), PC (38:3), PC (38: 4), PC (38: 5), PC (38: 6), PC (38: 7), PC (38: 8), PC (38: 9), PC (40: 5), PC (40: 6), PC (40;7), PC 40: 8), PC (40: 9), PC (44:12), PC-pmg (30:
1) , PC-pmg (36: 4), PC-pmg (38: 5), PC-pmg (38: 7), PC-pmg (40:11), PC-pmg (42: 1), PE (34: 7), PE (36: 5), PE (36: 7), PE (38: 2), PE (38: 3), PE (38: 4), PE (38: 5), PE (38: 7), PE (40: 4), PE (40: 9), PE (42:12), PE (44:11), PE-pmg (28:
2) , PE-pmg (30: 3), PE-pmg (34: 6), PE- pmg (34: 8), PE-pmg (36: 5), PE-pmg (36: 6), PE-pmg (40: 7), PE-pmg (40: 8), PE-pmg (42: 10), PE-pmg (42:12), PE-pmg (42: 4), PE-pmg (42: 7), PE-pmg (42: 8), PE-pmg (42: 9), PE-pmg (44:10), PE-pmg (44:11), PE-pmg (44:12), PE-pmg (44: 7), PE-pmg (44: 8), PE-pmg (44: 9) , PGA1 (20: 1), PGB1 (20: 1), SM (34: 1), SM (34: 2), SM (36: 1), SM (38: 1), SM (40: 1) SM (40: 2), SM (42: 1), SM (42: 2), SM (42: 3), sfingosin (18:
0) , TAG (44: 1), TAG (44: 3), TAG (46: 0), TAG (46: 1), TAG (46: 2), TAG (46:
3) , TAG (46: 4), TAG (48: 0), TAG (48: 1), TAG (48: 2), TAG (48: 3), TAG (48:
4) , TAG (48: 5), TAG (49: 1), TAG (49: 2), TAG (49: 3), TAG (50: 0), TAG (50:
1) , TAG (50: 2), TAG (50: 3), TAG (50: 4), TAG (50: 5), TAG (50: 6), TAG (51:
2) , TAG (51: 4), TAG (52: 2), TAG (52: 3), TAG (52: 4), TAG (52: 5), TAG (52:
6), TAG (52: 7), TAG (53: 4) TAG (54: 2), TAG (54: 3), TAG (54: 4), TAG (54:
5) , TAG (54: 6), TAG (54: 7), TAG (54: 8) TAG (55: 5), TAG (55: 6), TAG (55:
7), TAG (56: 4), TAG (56: 5), TAG (56: 6), TAG (56: 7), TAG (56: 8), TAG (56: 9), TAG (58:10), TAG (58: 6), TAG (58: 8), TAG (58: 9), TAG (60:12) og TH -12-keto-LTB4 (20: 2).
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter lungecancer, og en eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af LysoPA (22: 0), PE-pmg (42: 9), FA (16: 3), FA (19: 1), CE (18: 2), Cer (36: 1), Cer (38: 4), PC (38:
5) , Cer (38: 1), og TAG (44: 3).
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter lungecancer, og et eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af TAG (44: 3), PC (36: 5 ), PC (38: 5), Cer (38: 4), PE-pmg (42: 9), PC (38: 7), LysoPA (22: 0), Cer (38: 1), Cer (34: 1), Cer (36: 1), PC (40: 7), TAG (54: 5), TAG (54: 6), CE (18: 2), PC (36: 4), FA (16: 3), PE-pmg (44:11), TAG (52: 5), Cer (40: 4), CE (20: 5), PC (38: 6), TAG (50: 2), MAG (18: 0), FA (19: 1), TAG (52: 2), LysoPA (22: 1), MAG (24: 2), TAG (54: 7), TAG (50: 3), TAG (50: 1), DAG (36: 3), PC (34: 1), TAG (52: 6), PE-pmg (44:12), CE (20: 4), PE (44:11), PC (40: 8), TAG (56: 9), PE-pmg (34:
6) , PE (36: 7), PE (36: 5), TAG (56: 7), TAG (56: 8), DAG (34: 3), TAG (56: 6), TAG (52: 3), TAG (54: 3), TAG (56: 5), TAG (54: 8), PC (34: 6), PC (40: 6), DAG (36: 0), LysoPE (10: 1), DAG (40: 5), Cer (32: 1), TAG (50: 5), TAG (50:
4) , PE-pmg (36: 6), TAG (46: 3) og PE (38: 5).
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter lungecancer og et eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af TAG (44: 3), PC (36: 5), PC (38:
5) , Cer (38: 4), PE-pmg (42: 9), PC (38: 7), LysoPA (22: 0), Cer (38: 1), Cer (34: 1) og Cer (36: 1).
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancer type omfatter brystcancer, og en eller flere lipider i lipidsættet er yderligere valgt fra gruppen, der består af LysoPA (22: 1), PE-pmg (42: 9), CE (20: 5), TAG (52: 3), LysoPA (22: 0), PC (36: 3), PC (36: 4), PC (36: 2) PC (34: 2) og PC (34: 1).
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter brystcancer, og en eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af PC (34: 2), PC (34: 1 ), PC (36: 2), PC (36: 4), PC (36: 3), PC (38: 4), LysoPA (22: 1), PE-pmg (42: 9), LysoPA (22: 0), CE (20: 5), Cer (36: 1), CE (18: 2), DAG (34: 0), SM (34: 1), DAG (32: 0), PE-pmg (40: 8), PC (38: 3), DAG (36: 0), PC (36: 1), TAG (54: 5), TAG (54:
6) , PE-pmg (44:11), PMG (42: 8), TAG (52: 2), SM (42: 2), PC (38: 6), TAG (54:
7) , PC (40: 6), PC (40: 7), LysoPC (16: 0), FA (16: 3), TAG (52: 5), TAG (44: 3), SM (40: 1), PE-pmg (42:10), PE-pmg (40: 7), SM (36: 1), PE (38: 2), PC (34: 3), PC (36: 5), PC (32: 0), PC (32: 1), PC (36: 9), SM (42: 3), PC-pmg (36: 4), PC-pmg (38: 5), PC (40: 9), TAG (54: 3), PE-pmg (44:12), FA (19: 1), TAG (50: 3), PC (34: 6), GA2 (35: 2), TAG (58: 9), PE-pmg (42: 7) og LysoPC (18: 0) .
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter brystcancer, og en eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af PC (34: 2), PC (34: 1), PC (36:
2), PC (36: 4), PC (36: 3), PC (38: 4), LysoPA (22: 1), PE-pmg (42: 9), LysoPA 0) og CE (20: 5).
14. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter lungecancer og brystcancer, og en eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af LysoPA (22:
1) , PC (36: 5), TAG (52: 3), PC (38: 5), CE (20: 5), TAG (50: 2), PC (34: 2), CE (18: 2) og PC (34: 1).
15. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter lungecancer og brystcancer, og en eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af PC (34: 2), PC (36: 2), TAG (44: 3), CE (18: 2), PC (34: 1), LysoPA (22: 1), PC (36: 5), Cer (36: 1), CE 20: 5), PC (36: 3), PC (38: 4), PC (36: 4), Cer (38: 4), PC (38: 5), PC (38: 7), Cer (38: 1), TAG (50: 2), Cer (34: 1), SM (34: 1), Cer (40: 4), MAG (18: 0), MAG (24: 2) PC (38: 3), PE-pmg (40: 8), PE-pmg (42: 8), TAG (50: 1), DAG (32: 0), PC (36: 1), DAG (34: 0), LysoPC (16: 0), PE-pmg (34: 6), DAG (36: 3), PC (36: 9), PE (36: 5), TAG (52: 6), FA (19: 1), PE-pmg (44:11), PE (44:11), TAG (48: 2), SM (42: 2), PE-pmg (42:10), PE (36: 7), PE-pmg (40: 7), PE-pmg (36: 6), PE (38: 5), PC (32: 0), PE (38: 2), GA2 (35: 2), DAG (34: 3), PE-pmg (44:12), MAG (16: 0), PC (32: 1), LysoPE (10: 1), SM (36: 1), TAG (56: 7) og PE-pmg (42: 9).
16. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den mindst ene cancertype omfatter lungecancer og brystcancer, og en eller flere lipider i lipidsættet er yderligere udvalgt fra gruppen, der består af PC (34: 2), PC (36: 2), TAG (44: 3), CE (18: 2), PC (34: 1), LysoPA (22: 1), PC (36: 5), Cer (36:1), CE (20: 5) og PC (36: 3).
17. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor lipidmængderne bestemmes under anvendelse af massespektrometri, såsom en Fourier-transform-ion-cyklotron-resonansmasseanalysator.
18. Fremgangsmåden ifølge et hvilket som helst af de foregående krav, hvor prøven er en behandling af en kropsvæske, og behandlingen omfatter en eller flere ekstraktioner under anvendelse af en eller flere opløsninger, der omfatter acetonitril, vand, chloroform, methanol, butyleret hydroxytoluen, trichloreddikesyre eller kombinationer deraf.
19. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor den prædiktive model omfatter en eller flere dimensionsreduktionsfremgangsmåder.
20. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor den prædiktive model omfatter en eller flere fremgangsmåder, der er valgt fra gruppen, som består af principal komponentanalyse (PCA), blød uafhængig modellering af klasseanalogi (SIMCA), partielle mindste kvadraters diskriminantanalyse (PLS-DA), og ortogonale partielle mindste kvadrater diskriminantanalyse (OPLS-DA).
21. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor dyret er valgt fra gruppen bestående af human, hund, kat, hest, ko, gris, får, kylling, kalkun, mus og rotte.
22. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor den mindst ene cancertype er lunge- eller brystcancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35764210P | 2010-06-23 | 2010-06-23 | |
| PCT/US2011/041399 WO2011163332A2 (en) | 2010-06-23 | 2011-06-22 | Methods for detecting cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2585833T3 true DK2585833T3 (da) | 2017-09-18 |
Family
ID=45372067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11798823.8T DK2585833T3 (da) | 2010-06-23 | 2011-06-22 | Fremgangsmåder til detektering af cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20130109592A1 (da) |
| EP (4) | EP2585833B1 (da) |
| JP (3) | JP5944385B2 (da) |
| AU (3) | AU2011270968C1 (da) |
| CA (1) | CA2803865A1 (da) |
| DK (1) | DK2585833T3 (da) |
| ES (3) | ES2989530T3 (da) |
| WO (1) | WO2011163332A2 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012343843B2 (en) * | 2011-11-30 | 2018-03-08 | Metanomics Health Gmbh | Device and methods to diagnose pancreatic cancer |
| WO2014043633A1 (en) * | 2012-09-17 | 2014-03-20 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| MX369691B (es) | 2012-11-21 | 2019-11-19 | Agios Pharmaceuticals Inc | Inhibidores de glutaminasa y métodos de empleo. |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US11353467B2 (en) | 2013-01-24 | 2022-06-07 | The Regents Of The University Of California | Use of lipid particles in medical diagnostics |
| KR101408217B1 (ko) * | 2013-05-22 | 2014-06-17 | 국립암센터 | 질량분석패턴을 이용한 원발성간내담도암 및 전이성간암의 감별법 |
| AU2014368412A1 (en) * | 2013-12-20 | 2016-07-07 | Metanomics Health Gmbh | Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel |
| MX2016012244A (es) | 2014-03-21 | 2017-05-08 | Agios Pharmaceuticals Inc | Compuestos y sus metodos de uso. |
| EP2963608A1 (en) * | 2014-07-04 | 2016-01-06 | Tata Consultancy Services Limited | System and method for prescriptive analytics |
| US10758133B2 (en) * | 2014-08-07 | 2020-09-01 | Apple Inc. | Motion artifact removal by time domain projection |
| WO2017155473A1 (en) * | 2016-03-10 | 2017-09-14 | Agency For Science, Technology And Research | Lipid biomarkers for the diagnosis of cancer |
| JP6520893B2 (ja) | 2016-04-01 | 2019-05-29 | 株式会社デンソー | 運転支援装置及び運転支援プログラム |
| KR101812205B1 (ko) * | 2016-04-11 | 2017-12-26 | 연세대학교 산학협력단 | 혈청 대사체를 이용한 인후암 예측 방법 |
| WO2018013678A2 (en) * | 2016-07-13 | 2018-01-18 | Board Of Regents, The University Of Texas System | Molecular markers and methods for sample analysis via mass spectrometry |
| EP3496859B1 (en) | 2016-09-02 | 2024-01-10 | Board of Regents, The University of Texas System | Collection probe and methods for the use thereof |
| CA2964878A1 (en) * | 2016-10-14 | 2018-04-14 | Youping Deng | Lipid markers for early diagnosis of breast cancer |
| US20180246112A1 (en) * | 2017-02-28 | 2018-08-30 | University Of Kentucky Research Foundation | Biomarkers of Breast and Lung Cancer |
| EP3622295A1 (en) * | 2017-05-11 | 2020-03-18 | Servizo Galego de Saúde (SERGAS) | Cholesteryl linoleate (18:2) in feces samples as biomarker for colorectal cancer |
| CA3083260A1 (en) | 2017-11-27 | 2019-05-31 | Board Of Regents, The University Of Texas System | Minimally invasive collection probe and methods for the use thereof |
| EP3514545B1 (en) * | 2018-01-22 | 2020-10-07 | Univerzita Pardubice | A method of diagnosing pancreatic cancer based on lipidomic analysis of a body fluid |
| JP7086417B2 (ja) * | 2018-01-22 | 2022-06-20 | ウニベルシタ パルドゥビツェ | 体液のリピドミクス解析に基づいて癌を診断する方法 |
| CN109613131B (zh) * | 2018-11-27 | 2021-08-27 | 北京大学第三医院 | 基于尿液磷脂组学的肾损伤早期诊断标志物及应用 |
| KR102156217B1 (ko) * | 2019-03-05 | 2020-09-15 | 연세대학교 산학협력단 | 대장암 진단용 지질 바이오마커 및 이의 용도 |
| KR102156216B1 (ko) * | 2019-03-05 | 2020-09-15 | 연세대학교 산학협력단 | 위암 진단용 지질 바이오마커 및 이의 용도 |
| KR102156215B1 (ko) * | 2019-03-05 | 2020-09-15 | 연세대학교 산학협력단 | 갑상선암 진단용 지질 바이오마커 및 이의 용도 |
| KR102156214B1 (ko) * | 2019-03-05 | 2020-09-15 | 연세대학교 산학협력단 | 폐암 진단용 지질 바이오마커 및 이의 용도 |
| WO2022094404A1 (en) * | 2020-11-02 | 2022-05-05 | Iontrap LLC | Method and apparatus for the rapid detection of air-borne viruses |
| KR102421466B1 (ko) * | 2021-10-06 | 2022-07-18 | (주)이노베이션바이오 | 암 진단용 바이오마커 및 이의 용도 |
| CN117233367B (zh) * | 2023-11-16 | 2024-02-09 | 哈尔滨脉图精准技术有限公司 | 妊娠期高血压风险评估的代谢标志物 |
| CN119964640B (zh) * | 2025-01-06 | 2025-09-19 | 太原理工大学 | 一种基于正交最小二乘法与元分析的基因特征选择方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824555A (en) * | 1996-05-30 | 1998-10-20 | The Cleveland Clinic Foundation | Method of detecting gynecological carcinomas |
| IL131985A0 (en) * | 1997-03-21 | 2001-03-19 | Atairgin Biotechnologies Inc | Method for detecting cancer associated with altered concentrations of lysophospholipids |
| US7964408B1 (en) * | 2004-05-13 | 2011-06-21 | University Of South Florida | Lysophospholipids as biomarkers of ovarian cancer |
| WO2006044680A1 (en) * | 2004-10-14 | 2006-04-27 | The Cleveland Clinic Foundation | Methods of detecting colorectal cancer |
| CN101454331A (zh) * | 2006-03-24 | 2009-06-10 | 菲诺梅诺米发现公司 | 有效用于诊断前列腺癌的生物标记，及其方法 |
| GB2469244A (en) * | 2008-01-28 | 2010-10-06 | Univ Singapore | Lipid tumour profile |
| EP2310529A2 (en) * | 2008-06-20 | 2011-04-20 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
| BR112012019894A2 (pt) * | 2010-02-11 | 2016-05-03 | Univ Leuven Kath | "perfil fosfolipídeo e câncer" |
-
2011
- 2011-06-22 US US13/805,352 patent/US20130109592A1/en not_active Abandoned
- 2011-06-22 ES ES21200018T patent/ES2989530T3/es active Active
- 2011-06-22 AU AU2011270968A patent/AU2011270968C1/en active Active
- 2011-06-22 WO PCT/US2011/041399 patent/WO2011163332A2/en not_active Ceased
- 2011-06-22 EP EP11798823.8A patent/EP2585833B1/en active Active
- 2011-06-22 EP EP20176591.4A patent/EP3719502A1/en not_active Withdrawn
- 2011-06-22 JP JP2013516721A patent/JP5944385B2/ja active Active
- 2011-06-22 CA CA2803865A patent/CA2803865A1/en active Pending
- 2011-06-22 ES ES11798823.8T patent/ES2638522T3/es active Active
- 2011-06-22 EP EP17163073.4A patent/EP3206034B1/en active Active
- 2011-06-22 ES ES17163073T patent/ES2812457T3/es active Active
- 2011-06-22 EP EP21200018.6A patent/EP3955004B1/en active Active
- 2011-06-22 DK DK11798823.8T patent/DK2585833T3/da active
-
2015
- 2015-05-29 JP JP2015109485A patent/JP6092302B2/ja active Active
-
2016
- 2016-08-12 AU AU2016213855A patent/AU2016213855B2/en active Active
- 2016-09-23 JP JP2016185269A patent/JP2016218085A/ja active Pending
-
2018
- 2018-09-28 AU AU2018236876A patent/AU2018236876A1/en not_active Abandoned
-
2021
- 2021-07-15 US US17/305,824 patent/US20220003792A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2989530T3 (es) | 2024-11-26 |
| WO2011163332A2 (en) | 2011-12-29 |
| EP3206034A2 (en) | 2017-08-16 |
| JP6092302B2 (ja) | 2017-03-08 |
| EP3719502A1 (en) | 2020-10-07 |
| EP3955004A2 (en) | 2022-02-16 |
| EP3206034B1 (en) | 2020-05-27 |
| AU2011270968A1 (en) | 2013-01-24 |
| AU2016213855B2 (en) | 2018-07-05 |
| AU2018236876A1 (en) | 2018-10-18 |
| JP2013529784A (ja) | 2013-07-22 |
| ES2638522T8 (es) | 2021-02-11 |
| WO2011163332A9 (en) | 2012-04-26 |
| EP3955004C0 (en) | 2024-05-29 |
| US20220003792A1 (en) | 2022-01-06 |
| EP3955004A3 (en) | 2022-05-11 |
| ES2638522T3 (es) | 2017-10-23 |
| JP5944385B2 (ja) | 2016-07-05 |
| EP3955004B1 (en) | 2024-05-29 |
| AU2016213855A1 (en) | 2016-09-01 |
| JP2016218085A (ja) | 2016-12-22 |
| ES2812457T3 (es) | 2021-03-17 |
| EP2585833A4 (en) | 2013-11-13 |
| EP3206034A3 (en) | 2017-10-11 |
| JP2015158512A (ja) | 2015-09-03 |
| EP2585833A2 (en) | 2013-05-01 |
| US20130109592A1 (en) | 2013-05-02 |
| EP2585833B1 (en) | 2017-05-31 |
| AU2011270968C1 (en) | 2017-01-19 |
| CA2803865A1 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2585833T3 (da) | Fremgangsmåder til detektering af cancer | |
| AU2011270968B2 (en) | Methods for detecting cancer | |
| Jové et al. | A plasma metabolomic signature discloses human breast cancer | |
| Xiao et al. | LC–MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort | |
| Rocha et al. | Mass spectrometry imaging: a novel technology in rheumatology | |
| De Guzman et al. | Chronic caloric restriction partially protects against age-related alteration in serum metabolome | |
| JP2016153808A (ja) | 前立腺癌を診断する手段と方法 | |
| US20150160238A1 (en) | Means and Methods for Diagnosing and Monitoring Heart Failure in a Subject | |
| Garate et al. | Influence of lipid fragmentation in the data analysis of imaging mass spectrometry experiments | |
| Lloyd et al. | Ultra high performance liquid chromatography–high resolution mass spectrometry plasma lipidomics can distinguish between canine breeds despite uncontrolled environmental variability and non-standardized diets | |
| Caponigro et al. | Integrated plasma metabolomics and lipidomics profiling highlights distinctive signature of hepatocellular carcinoma in HCV patients | |
| Qi et al. | Cholesterol was identified as a biomarker in human melanocytic nevi using DESI and DESI/PI mass spectrometry imaging | |
| Liu et al. | Discovery of lipid profiles in plasma‐derived extracellular vesicles as biomarkers for breast cancer diagnosis | |
| Mason et al. | Lipidomic profiling of colorectal lesions for real-time tissue recognition and risk-stratification using rapid evaporative ionization mass spectrometry | |
| HK40062522B (en) | Use of fatty acids in methods for detecting cancer | |
| HK40062522A (en) | Use of fatty acids in methods for detecting cancer | |
| HK1180764A (en) | Methods for detecting cancer | |
| HK1180764B (en) | Methods for detecting cancer | |
| EP4522996A1 (en) | Diagnostic signature | |
| Eckel et al. | Application of rapid evaporative ionization mass spectrometry in preclinical and clinical analyses of steatotic liver tissues and cells | |
| Mutuku et al. | MALDI Mass spectrometry imaging in lipidomics | |
| Altadill | Metabolomic study for the identification of diagnostic markers and the characterization of the dissemination process of endometrial cancer | |
| ES2734810T3 (es) | Uso de SM_Esfingomielina (D18:1, C16:0) como un marcador para insuficiencia cardiaca | |
| Shaheed | Oncoproteomic applications for detection of breast cancer. Proteomic profiling of breast cancer models and biopsies | |
| Gathercole | Biomarker discovery for pre-clinical diagnosis of Tasmanian devil facial tumour disease |